Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014222 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
A Phase 3 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,104
- Enrollment target
NCT00014222: Completed Phase 3 study, sponsored by NCIC Clinical Trials Group.
NCT00014222 is a Phase 3 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 2,104 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014222, a Phase 3 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,104 participants
- Enrollment target
Study Summary
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Primary Outcome
Disease free survival was defined as the time from randomization to the time of recurrence of the primary disease. Local or nodal recurrence and metastatic disease were considered a recurrence of the primary tumour. Patients who had contralateral breast cancer or a second primary malignancy, or died from some cause other than disease were censored as relapse-free at the time of death. Patients who had not relapsed were censored at longest follow-up or at non-breast cancer death. As required, adj
Interventions
- DRUG cyclophosphamide
- DRUG epirubicin hydrochloride
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,104 participants |
| Start Date | 2000-12-04 |
| Est. Completion | 2014-03-17 |
| Phase | Phase 3 |
What the finished NCT00014222 record still lists
NCT00014222 is an interventional study that assigns participants to a tested intervention. Its 2,104 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00014222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014222 about?
NCT00014222 is a clinical study titled "Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer". RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ...
What is the current status of trial NCT00014222?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,104 participants. The study started on 2000-12-04. Estimated completion is 2014-03-17.
What interventions are being tested in trial NCT00014222?
The interventions under investigation include: cyclophosphamide (DRUG), epirubicin hydrochloride (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014222?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00014222's enrollment target sits among peer trials
2,104 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI